PharmaMar to present data on anticancer candidates PM1183 and plitidepsin at the AACR
American Association for Cancer Research Annual Meeting April 18-22, 2015 Combination of the anticancer drug PM1183 with PARP inhibitors and doxorubicin results in a synergistic effect...